113 results about "Cellular immunity" patented technology

The invention discloses an echinococcosis mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application thereof. The preparation method of the mRNA vaccine for the echinococcosis comprises the following steps: carrying out codon optimization on a modified target antigen protein, then assembling the modified target antigen protein with 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a pUC57 plasmid, and sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmid to prepare an mRNA molecule, thereby obtaining the mRNA vaccine for the echinococcosis. Finally, mRNA molecules are wrapped in lipid nanoparticles through a microfluidic method to form the mRNA vaccine for the echinococcosis, and immune effect evaluation is carried out on the mRNA vaccine for the echinococcosis. Experiments prove that the prepared mRNA vaccine for the echinococcosis can activate humoral immunity and cellular immunity of mice at the same time, can provide an effective protection effect for the mice attacking insects, and has a wide application prospect in the aspect of preventing and / or treating the echinococcosis.

The invention discloses a ganoderma lucidum peptide for enhancing immunity as well as a preparation method and application thereof, and belongs to the technical field of functional peptide preparation. The ganoderma lucidum peptide provided by the invention contains various active ingredients / nutritional ingredients, is high in utilization rate of ganoderma lucidum, can improve the health level of intestinal tracts, promotes absorption and utilization of nutrient substances by the intestinal tracts, and provides a fundamental material guarantee for improving the immunity of the organism; immune cells are activated, and related lymphatic tissues of intestinal tracts are stimulated, so that the effects of regulating cellular immunity and humoral immunity levels are achieved; the preparation method provided by the invention does not use high-temperature, high-pressure and toxic and harmful reagents, has mild conditions, and is simple, easy to operate and environment-friendly; no toxic and harmful substances are generated, and generated filter residues can be directly used as animal feed or plant fertilizer; the prepared ganoderma lucidum peptide is small in molecule, high in activity, rich in active substance variety, high in yield and easy to absorb and utilize by organisms.

The invention belongs to the technical field of medicines, and discloses application of an adeno-associated virus vector in preparation of medicines for preventing and treating RSV infection and / or diseases caused by RSV. According to the invention, a recombinant adeno-associated virus vector is adopted for the first time to construct a medicine for preventing and treating RSV infection or diseases caused by RSV infection, and based on this, the invention provides a nucleic acid molecule which comprises: (a1) a first region which comprises a first adeno-associated virus inverted terminal repeat sequence, and (a2) a second region which comprises a second adeno-associated virus inverted terminal repeat sequence; and (a2) a second region comprising a gene encoding a respiratory syncytial virus antigen; the recombinant adeno-associated virus containing the nucleic acid molecule can generate better humoral immune effect and cellular immune effect, has a certain serum neutralization effect on strains of A and B subtypes of RSV, and particularly, when the antigen is a fusion protein of the respiratory syncytial virus or a fusion protein mutant of the respiratory syncytial virus, the recombinant adeno-associated virus has a certain serum neutralization effect on the strains of A and B subtypes of the RSV. The recombinant adenovirus vector containing the nucleic acid molecule can successfully realize the expression of the F protein before RSV fusion.

The application provides a cell fixing solution for a myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) and a product and application thereof, and relates to the technical field of in-vitro detection. The cell fixing solution provided by the application is composed of polyoxymethylene, formaldehyde, acetic acid, raffinose and a buffer solution, can effectively fix the cell morphology, maximally retains the natural spatial conformation and antigen epitope integrity of myasthenia gravis related antigens AChR, Titin, RyR1, MuSK and LRP4, reduces the problems of antigen denaturation, epitope shielding and protein loss in the fixing process, can efficiently and accurately realize the synchronous joint detection of various specific antibodies, and the myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) prepared by the application has stable detection results, and has important clinical application value and industrial popularization prospect.

This invention relates to the field of biopharmaceutical technology, disclosing a QS-21 saponin adjuvant, its preparation method, and its applications. The adjuvant is a composite liposome comprising a liposome backbone composed of distearate phosphatidylcholine and cholesterol, with QS-21 saponin, monophosphatidyllipid A, and a local anesthetic co-encapsulated therein. This invention solves the common problem of high reactivity and immunogenicity in potent adjuvants by co-encapsulating immunostimulatory and analgesic components on the same nanocarrier, achieving synergistic delivery at the injection site, thereby precisely inhibiting adjuvant-induced pain and swelling. This co-encapsulation structure avoids the potential inhibitory effect of free anesthetics on the immune system, fully preserving the adjuvant's potent humoral and cellular immune-enhancing activity. This invention provides a new technical solution for developing vaccines with both high safety and strong immunogenicity.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

The invention discloses a blocking agent for cell immunofluorescence detection by a slide method and a use method of the blocking agent. The blocking agent is a homologous no-load cell lysis solution without transfection plasmids, and the protein concentration is greater than or equal to 30mg / mL. The blocking agent is completely the same as cell cytoplasm and cell membrane components of cells to be detected except for plasmids-expressed antigens, when in use, the blocking agent is pre-mixed with a blood cleaning sample in advance, interfering antibodies except target antibodies in serum can be purified, and meanwhile, due to the fact that no antigen protein expressed after plasmid transfection exists, the blocking agent can be used for detecting the cells to be detected. And the protein concentration is equivalent to the globulin concentration in serum, so that the target antibody cannot be lost in the serum, and the slide method CBA detection sensitivity can be greatly improved.

The invention discloses a CAR-T cell for targeted knockout of a CMPK2 gene, a preparation method of the CAR-T cell and application of the CAR-T cell in solid tumor resistance, and belongs to the technical field of tumor immunotherapy. Experiments prove that the targeted knockout of the CMPK2 gene can improve the capability of killing HepG2 tumor cells in vitro by CAR-T cells; in addition, after targeted knockout of the CMPK2 gene, the killing ability of CAR-T cells on NSG mouse liver cancer solid tumors can be improved, and it is proved that the CMPK2 target has great clinical cellular immunotherapy potential. According to the invention, the problem that the efficacy of the traditional CAR-T cell therapy is reduced in solid tumor treatment is solved, the anti-tumor activity and the treatment effect of the CAR-T cells are remarkably improved, meanwhile, higher safety and applicability are ensured, and the CAR-T cells have important clinical application value and wide development prospects.

The invention belongs to the technical field of gene engineering, and particularly relates to recombinant lactobacillus for expressing clostridium perfringens multiple antigens of targeted dendritic cells as well as a construction method and application of the recombinant lactobacillus. The recombinant lactobacillus contains an expression vector for expressing a fusion gene; the fusion gene comprises sequences for coding and expressing a PgsA '-fimA fusion protein, a LysM-Fba fusion protein, an LP1261-NetB fusion protein, a phi54 targeting element and a Pas escape element; a sequence for coding the PgsA '-fimA fusion protein is shown as SEQ ID NO: 1, a sequence for coding the LysM-Fba fusion protein is shown as SEQ ID NO: 2, and a sequence for coding the LP1261-NetB fusion protein is shown as SEQ ID NO: 3. When the recombinant lactobacillus is used for immunizing animals, mucosal immunity, cellular immunity and humoral immunity reactions can be induced, the immunocompetence of organisms can be comprehensively enhanced, and the recombinant lactobacillus can be used for preparing oral vaccines for prevention and control of chicken necrotic enteritis.

The invention relates to the technical field of mRNA vaccine preparation, and particularly discloses a porcine epidemic diarrhea virus mRNA vaccine and a preparation method thereof. The mRNA vaccine is prepared by adopting cow milk source exosome as a carrier and wrapping mRNA encoding PEDV-S protein in the carrier through an ultrasonic loading method. According to the preparation method, the encapsulation efficiency of mRNA and the stability of the vaccine are remarkably improved, the prepared vaccine can more efficiently promote antigen expression, stronger cellular immunity and humoral immunity are induced in a mouse body, and a safe and efficient novel vaccine candidate is provided for preventing and controlling porcine epidemic diarrhea.

The application discloses application of sodium butyrate in preparation of a medicine for preventing and treating grass carp hemorrhagic disease, wherein a structural formula of the sodium butyate is molecular formula C4H7NaO2, and a CAS number is 156-54-7; and the application further provides a medicine composition which comprises an effective dose of the sodium butyrate as an active ingredient, and further comprises a pharmaceutically acceptable carrier or excipient, and the dosage form comprises tablets, granules, powders, powders, suspensions, oral liquids, and the concentration of the sodium butyrate is 0.1-20 mM. Through a cell experiment, it is found that the sodium butyrate can significantly inhibit replication of grass carp reovirus in grass carp kidney cells, and improve expression of immune genes of the grass carp kidney cells, and it is proved that the sodium butyrate has a high efficient inhibiting effect on infection of the grass carp reovirus, and has the advantages of high safety and wide application prospect for preparing the medicine for preventing and treating the grass carp hemorrhagic disease caused by the grass carp reovirus.

A method for treating a tumor, characterized by administering to an individual having a tumor immune effector cells expressing a receptor recognizing a tumor antigen and gemcitabine. A kit for treating a tumor, characterized by comprising: 1) immune effector cells expressing a receptor recognizing a tumor antigen; 2) gemcitabine; 3) a container for containing the above 1) and 2); and 4) a written notice for treating a tumor using the kit.

The present disclosure relates to methods for determining the magnitude of a subject's immune response against a HIVACAT T-cell immunogen (HTI or “HTI immunogen”) and whether the subject can avoid antiretroviral therapy (ART). These methods are helpful for treating human immunodeficiency virus (HIV) and / or deciding whether to administer, continue or stop antiretroviral therapy in a subject. The present disclosure also relates to antigens, compositions, and kits related to such methods.

A method for treating a tumor, characterized by administering to an individual having a tumor immune effector cells expressing a receptor recognizing a tumor antigen and gemcitabine. A kit for treating a tumor, characterized by comprising: 1) immune effector cells expressing a receptor recognizing a tumor antigen; 2) gemcitabine; 3) a container for containing the above 1) and 2); and 4) a written notice for treating a tumor using the kit.

The present application relates to the technical fields of biological medicine and cellular immunotherapy, and particularly relates to a signal conversion receptor targeting IL-10, an engineered macrophage and application thereof. The signal conversion receptor is composed of an extracellular domain and a transmembrane domain and an intracellular domain derived from TLR9, and the extracellular domain sequentially comprises a signal peptide, a HA tag and a specific binding domain of an IL-10 receptor alpha subunit from N-terminal to C-terminal. The present application further prepares an engineered macrophage SR CAR-M capable of specifically recognizing IL-10 and converting it into a TLR9 activation signal, which can induce macrophages to polarize to M1 type and has excellent phagocytosis and killing capacity for bladder cancer, breast cancer, lung cancer and melanoma cells, and can be used for preparing related tumor treatment drugs, overcoming the common problems of existing cell therapy, such as easy exhaustion, difficult infiltration and easy inhibition in solid tumors, and having significant clinical transformation potential.

The invention belongs to the technical field of biology, and particularly relates to a recombinant monoclonal antibody of sheep anti-bluetongue virus VP7 protein. A sheep anti-bluetongue virus antibody library is obtained through a single cell V (D) J sequencing technology, a sheep anti-bluetongue virus VP7 protein recombinant monoclonal antibody is screened and successfully expressed, and it is identified through indirect ELISA and cellular immunofluorescence experiments that the recombinant monoclonal antibody has high affinity with bluetongue virus and can be specifically combined with VP7 protein. The recombinant monoclonal antibody is used as a competitive antibody to establish a competitive ELISA detection method aiming at the bluetongue virus VP7 protein, high specificity of bluetongue antibody detection can be realized, and a basis is provided for mastering the epidemiology of bluetongue virus and evaluating the immune effect of vaccines.

The invention belongs to the technical field of veterinary biological products, and relates to an mRNA freeze-dried vaccine of a porcine epidemic diarrhea virus as well as a preparation method and application of the mRNA freeze-dried vaccine. When the mRNA vaccine is prepared, firstly, the S gene sequences of the porcine epidemic diarrhea virus GIIa type and the porcine epidemic diarrhea virus GIIc type which are separated and stored in a laboratory are selected; the preparation method comprises the following steps: firstly, carrying out codon optimization, then respectively connecting with 5 'UTR, 3' UTR, a termination codon and a polyA tail nucleic acid sequence in series, connecting to a vector, carrying out in-vitro template transcription, carrying out in-vitro transcription, capping and purifying to obtain mRNA, and finally, encapsulating and freeze-drying to prepare the mRNA vaccine. The invention further provides application of the vaccine to immunization of pigs, cellular immunity and humoral immunity in the pigs can be stimulated, the immunogenicity and protective efficacy of the vaccine are superior to those of commercially available bivalent live vaccines, and the vaccine can be used for preventing porcine diarrhea caused by infection of currently epidemic PEDV GIIa and GIIc type strains.

The application discloses a mycobacterium tuberculosis tandem DNA vaccine W545 and a preparation method and application thereof. The application constructs a novel mycobacterium tuberculosis DNA vaccine W545 with a multi-antigen immune dominant epitope by connecting epitope genes of Ag85A protein and Ag85B protein antigen and Rv1419, Rv3407 and Rv2628c together in series through genetic engineering technology and connecting the epitope genes to a eukaryotic expression vector pVAX1. The prepared mycobacterium tuberculosis tandem DNA vaccine W545 can significantly enhance specific cellular immune function of mice, mainly stimulates Th1 type immune response, and can make the lesion range of organs and tissues of a mouse tuberculosis model significantly reduced and the lesion alleviated in treatment, and can be used in preparation of drugs or vaccines for preventing or treating tuberculosis.

This invention belongs to the field of biodetection technology, specifically relating to a material for detecting anti-Caspr1 antibodies and its preparation method. The invention constructs an expression plasmid capable of highly expressing the Caspr1 antigen, transfects it into HEK293T cells, and modifies the original antigen sequence during construction to achieve normal membrane expression. Subsequently, a modified cell culture protocol is used to obtain a material for detecting anti-Caspr1 antibodies based on cellular immunofluorescence assay. This invention, based on cellular immunofluorescence, avoids the limitations of flow cytometry, which is complex and requires expensive equipment. By modifying the protein expression mode to normal membrane expression, it avoids cell permeabilization, avoids false negatives caused by antigen conformational changes in enzyme-linked immunosorbent assay (ELISA) and Western blotting, and avoids false negatives caused by transmembrane expression due to transfection with the original Caspr1 sequence.

The present application belongs to the technical field of cellular immunization engineering, and particularly relates to a polypeptide specifically recognizing PSCA and application thereof. The polypeptide provided by the present application specifically recognizes PSCA and has good affinity performance. The polypeptide specifically targeting PSCA provided by the present application can mark PSCA positive cells, combine with PSCA antigen and PSCA positive cells, and can be used as a detection reagent for PSCA molecules and an in-vivo tracing labeling reagent. The polypeptide specifically targeting PSCA provided by the present application can also be used in an extracellular antigen recognition region of a chimeric antigen receptor, and can be used in an immune cell treatment drug targeting PSCA to kill malignant tumors expressing PSCA. The polypeptide specifically recognizing PSCA of the present application is derived from a natural full human antibody, and compared with a mouse-derived antibody, a chimeric antibody and a humanized antibody, the immunogenicity is greatly reduced, and the safety can be maximally ensured in clinical application.

The invention is applicable to the field of gene engineering, and provides a mycobacterium tuberculosis ESAT-6-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis ESAT-6-LS protein nanoparticle is formed by sequence fusion of mycobacterium tuberculosis ESAT-6 protein and LS protein, and the amino acid sequence of the mycobacterium tuberculosis ESAT-6-LS protein nanoparticle is shown as SEQ ID NO: 2 in a sequence table. The ESAT-6-LS protein nanoparticle provided by the invention is non-toxic and free of pathogenicity, can ensure that a vaccine has good biological safety, and is suitable for clinical application. Animal experiments show that after a mouse is immunized by the ESAT-6-LS protein nanoparticle, strong humoral immunity (antibody generation) and cellular immunity (T cell response) can be stimulated at the same time, and it is proved that the recombinant ESAT-6-LS protein nanoparticle vaccine can effectively induce specific immune protection.

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating various pathogenic enterobacter infections, as well as a molecular architecture design, application and the like. According to the invention, three cellular immune antigens Tuf, DnaK and fusA are screened, and the constructed fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by various enterobacter infections, have good immunogenicity, play roles in effective prevention and immune protection, and broad-spectrum and efficient prevention of various pathogenic enterobacter infections, and have broad industrial application prospects.

This invention belongs to the field of biodetection technology, specifically relating to a material for detecting anti-NF155 antibodies and its preparation method. This invention constructs an expression plasmid capable of highly expressing the NF155 antigen, transfects it into HEK293T cells, and modifies the pCDH vector with enhancers during construction. Subsequently, a modified cell culture protocol is used to obtain a material for detecting anti-NF155 antibodies based on a cell immunofluorescence methodology. This invention uses a cell immunofluorescence methodology to maximize the preservation of the antigen's spatial conformation through cell expression and antigen immobilization, preventing false negatives due to changes in binding sites. This invention selects the lentiviral vector pCDH to avoid the problem of non-specific binding that is difficult to distinguish, as the proteins expressed by common target gene vectors such as pcDNA3.1 may themselves contain antibody binding sites. This improves detection specificity and solves the problem of false negatives.

To provide an IL-12 production promoter containing honey as an active ingredient. [Solution] A composition for activating cellular immunity, containing sunflower honey as an active ingredient.

The invention discloses a biomarker combination for predicting the treatment effect of AK112 and application of the biomarker combination. The biomarker combination is prepared from APOE + KRT18-CCL20-macrophages, CD161 + CD8 + T cells, PDCD1, FGF2, diglyceride and lysophosphatidylcholine. Flow cytometry immunophenotypes (macrophage subgroups and T cell subgroups), plasma protein markers (PDCD1 and FGF2) and metabolic micromolecules (diglyceride and lysophosphatidylcholine) are combined to form a cross-omics prediction system, the combination can synchronously evaluate dual action mechanisms (immune activation and blood vessel regulation) of AK112, the technical bottleneck of single dimension of existing liquid biopsy is broken through, and the application prospect is wide. And a non-invasive dynamic monitoring tool is provided for accurately screening AK112 benefit people.

The present disclosure relates to the fields of molecular biology, more specifically antigen-binding molecule technology. The present disclosure also relates to methods of medical treatment and prophylaxis, particularly cellular immunotherapy.

The invention relates to the technical field of cellular immunotherapy, in particular to application of drafenib mesylate in preparation of a dendritic cell (DCs) immunologic adjuvant. The invention provides an application of drafenib mesylate in preparation of a dendritic cell immunologic adjuvant. It is found that darfenib mesylate can promote the maturation and migration functions of DCs, and the migration ability of DCs is remarkably improved. The DCs activation aspect of the darfenib mesylate comprises improvement of expression of maturation indexes CD80, CD40 and CD86 and expression of a migration index CCR7. Darrafenib mesylate used in the invention is a chemotherapeutic drug approved by FDA for clinical treatment of patients with BRAF V600 mutation positive non-resectable or metastatic melanoma, the application of Darrafenib mesylate in immunotherapy is discovered, new use of old drugs is realized, and the Darrafenib mesylate has significant economic value.

The invention relates to the technical field of antibodies, and particularly provides an anti-human TTC22v1 monoclonal antibody, a hybridoma cell strain prepared from the anti-human TTC22v1 monoclonal antibody and application of the anti-human TTC22v1 monoclonal antibody. The monoclonal antibody can specifically recognize the 432 -569 amino acid region of the TTC22v1 protein, and is secreted by a hybridoma cell strain TTC22v1-06 # with the preservation number of CCTCC (China Center For Type Culture Collection) NO: C202594. The antibody has high specificity and high sensitivity, can obviously distinguish TTC22v1 and TTC22v2 proteins, is especially suitable for Western blot and cell immunofluorescence detection, can effectively detect expression of endogenous TTC22v1 proteins in colon cancer cells, provides a reliable detection tool for research of TTC22v1 in tumor research and disease diagnosis, and has a wide application prospect.